Kymab strengthens management team
This article was originally published in Scrip
Cambridge, UK-based Kymab, a monoclonal antibody biopharmaceutical company, has named Steve Arkinstall chief scientific officer and Nigel Clark president and head of business development. Mr Arkinstall joins the company from Merck Serono where he held a number of senior management roles including leadership of the Serono Research Institute in Boston as well as head of global technologies and external innovation. He succeeds Allan Bradley as CSO at Kymab. Mr Bradley, a founder of the company, will remain on the executive leadership team.
You may also be interested in...
In this latest instalment of the In Vivo podcast Daniel Lofaso, CEO of Digital Elevator, talks about the common mistakes biotech companies make when trying to build their brand, how to connect with varied audiences and key trends the industry should keep track of in digital marketing.
Andrew Hopkins, founder and CEO of Exscientia, invented and championed an algorithmic approach to drug design and drug discovery. He talks to In Vivo about artificial intelligence in the biopharma industry today and what lies ahead.
Private drug developer Fabre-Kramer is expecting approval for its antidepressant gepirone hydrochloride in September 2023. The drug has been rejected multiple times by the FDA as a treatment for major depressive disorder.